Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease

Gut

Volumn 59, Issue 11, 2010, Pages 1586-1587

  Lewis, James D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

CROHN DISEASE; HUMAN; INCIDENCE; LETTER; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; EPIDEMIOLOGY; METHODOLOGY; NOTE; STATISTICAL ANALYSIS;

ANTIBODIES, MONOCLONAL; BIAS (EPIDEMIOLOGY); CROHN DISEASE; DATA INTERPRETATION, STATISTICAL; GASTROINTESTINAL AGENTS; HUMANS; RESEARCH DESIGN;

EID: 78049490535     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.191015     Document Type: Letter

References (3)

1. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8.
2. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007;16:241-9.
3. Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428-35.